Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
about
Pioglitazone use and risk of bladder cancer: population based cohort study.The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cellsGlucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialPioglitazone after Ischemic Stroke or Transient Ischemic Attack.Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.Taking care of volunteers in a stroke trial: a new assisted-management strategy.Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.Higher Insulin Resistance Level is Associated with Worse Clinical Response in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.Smoking cessation and outcome after ischemic stroke or TIA.The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone.
P2860
Q34676639-3A6DD73F-51DF-419F-B759-34691B242B60Q35196195-28D87643-17BA-4F19-9A03-FE3EF24BAF8EQ36217472-4321B44B-27A8-4269-A80F-400A96420E7AQ36548054-9B521EBC-D342-4A55-9B92-0AA2501E171DQ36820255-A247BE36-90E2-4BF7-AE1A-CE91A6E2F3E6Q36953272-69C5B601-4DD3-49E4-922C-837AA265819FQ38380127-87BF850D-82D2-41A8-9CC8-0B56A4412570Q41640163-5987E694-80D3-43BE-8886-92D97F613BBEQ41678642-072C2B8A-906F-44C5-80CD-DC6349D74496Q45939225-37976F19-EBB2-4F9A-9DE3-FF468F2AD378Q47380989-1680518E-35B4-4C06-9060-A98AB16C8E6FQ47739408-CC3D575B-2767-4882-B03E-301D032234B5Q48249929-6CDA08B4-1AD9-437E-A7CF-788F82FC4752Q48569413-67A60E18-13F9-4A80-A8A0-057DC7B1A88CQ53788212-E19F9DF4-3321-4C2F-81AB-7CAA18AA4E7D
P2860
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@ast
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@en
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@nl
type
label
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@ast
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@en
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@nl
prefLabel
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@ast
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@en
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@nl
P2093
P2860
P1476
Pioglitazone for secondary pre ...... tervention after Stroke Trial.
@en
P2093
Anne M Lovejoy
Antonio Carolei
Catherine M Viscoli
David Tanne
Gary A Ford
Gregory G Schwartz
IRIS Trial investigators
Karen L Furie
Lawrence H Young
Lawrence M Brass
P2860
P304
P356
10.1016/J.AHJ.2014.07.016
P407
P577
2014-07-28T00:00:00Z